Literature DB >> 24554064

Anaplastic thyroid carcinoma: a 25-year single-institution experience.

A Mohebati1, M Dilorenzo, F Palmer, S G Patel, D Pfister, N Lee, R M Tuttle, A R Shaha, J P Shah, I Ganly.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is among the most aggressive solid tumors accounting for 1-5 % of primary thyroid malignancies. In this retrospective review, we aim to evaluate the prognostic factors, treatment approaches, and outcomes of patients with ATC treated at a single institution.
MATERIALS AND METHODS: We retrospectively identified 95 patients with ATC from an institutional database between 1985 and 2010. A total of 83 patients with sufficient records were included in this study. Patient, tumor, and treatment characteristics were recorded. Disease-specific survival (DSS) was determined by the Kaplan-Meier method, and factors predictive of outcome were determined by univariate and multivariate analysis.
RESULTS: Of the 83 patients, 41 were male and 42 were female. The median age at presentation was 60 years (range 28-89 years) with a median survival of 8 months. The 1- and 2-year DSS were 33 and 23 %, respectively. On univariate analysis, age less than 60 years, clinically N0 neck, absence of clinical extrathyroidal extension (cETE), gross total resection, and multimodality treatment were statistically significant predictors of improved survival. On multivariate analysis, absence of cETE, multimodality therapy, and gross total resection were predictors of improved outcome.
CONCLUSIONS: In patients with locoregional limited disease, multimodality treatment with gross total surgical resection and postoperative radiotherapy with or without chemotherapy offers the best local control and DSS.

Entities:  

Mesh:

Year:  2014        PMID: 24554064     DOI: 10.1245/s10434-014-3545-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

1.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

2.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

3.  Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.

Authors:  Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn
Journal:  Cancer       Date:  2016-12-27       Impact factor: 6.860

4.  Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.

Authors:  H Vulpe; J Y Y Kwan; A McNiven; J D Brierley; R Tsang; B Chan; D P Goldstein; L W Le; A Hope; M Giuliani
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

5.  Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.

Authors:  Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins
Journal:  Head Neck       Date:  2019-12-16       Impact factor: 3.147

6.  TMEM158 May Serve as a Diagnostic Biomarker for Anaplastic Thyroid Carcinoma: An Integrated Bioinformatic Analysis.

Authors:  Han-Ning Li; Ya-Ying Du; Tao Xu; Rui Zhang; Ge Wang; Zheng-Tao Lv; Xing-Rui Li
Journal:  Curr Med Sci       Date:  2021-01-11

7.  Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.

Authors:  Dan Fan; Jennifer Ma; Andrew C Bell; Andries H Groen; Kyrie S Olsen; Benjamin H Lok; Jonathan E Leeman; Erik Anderson; Nadeem Riaz; Sean McBride; Ian Ganly; Ashok R Shaha; Eric J Sherman; C Jillian Tsai; Jung J Kang; Nancy Y Lee
Journal:  Cancer       Date:  2019-10-08       Impact factor: 6.860

8.  Multimodal treatment based on thyroidectomy improves survival in patients with metastatic anaplastic thyroid carcinoma: a SEER analysis from 1998 to 2015.

Authors:  Tao Song; Long Chen; Haibo Zhang; Yanwei Lu; Kun Yu; Wenming Zhan; Min Fang
Journal:  Gland Surg       Date:  2020-10

9.  Anaplastic Thyroid Cancer: Large Database, Cautious Interpretations.

Authors:  Ashok R Shaha
Journal:  Ann Surg Oncol       Date:  2015-07-29       Impact factor: 5.344

Review 10.  Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Histol Histopathol       Date:  2020-11-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.